Activity ID
14097Expires
July 23, 2026Format Type
EnduringCME Credit
0.5Fee
$0CME Provider: Clinical Care Options, LLC
Description of CME Course
The goal of this activity is to provide sustained education that will improve healthcare professionals’ knowledge, competence, and performance in adopting the latest best practices to optimize care of patients with schizophrenia.
ABMS Member Board Approvals by Type
ABMS Lifelong Learning CME Activity
Psychiatry and Neurology
Commercial Support?
YesNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
1. Define the distinctive mechanisms of action and pharmacokinetic characteristics of novel and emerging therapeutic agents for schizophrenia that extend beyond traditional antidopaminergic approaches
2. Assess efficacy and safety data, adverse events of novel and emerging treatments for schizophrenia
3. Explain the clinical utility of novel agents to address unmet needs of current schizophrenia treatments
Keywords
Muscarinic receptor
Competencies
Medical Knowledge
CME Credit Type
AMA PRA Category 1 Credit
Practice Setting
Academic Medicine, Inpatient, Outpatient, Rural, Urban, VA/Military
